Turnover of type III collagen reflects disease severity and is associated with progression and microinflammation in patients with IgA nephropathy

Nephrology Dialysis Transplantation

Volumn 31, Issue 3, 2016, Pages 472-479

  Genovese, Federica ^a   Boor, Peter ^b,c   Papasotiriou, Marios ^b,d   Leeming, Diana J ^a   Karsdal, Morten A ^a   Floege, Jürgen ^b  

^a NORDIC BIOSCIENCE A S   (Denmark)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c Faculty of Natural Sciences   (Slovakia)

^d UNIVERSITY HOSPITAL OF PATRAS   (Greece)

Author keywords

biomarkers; collagen; fibrosis; IgAN; turnover

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; AZATHIOPRINE; C REACTIVE PROTEIN; COLLAGEN TYPE 3; CORTICOSTEROID; CREATININE; CYCLOPHOSPHAMIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; BIOLOGICAL MARKER;

ADULT; ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DISEASE SEVERITY; DRUG EFFICACY; DRUG USE; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; IMMUNOGLOBULIN A NEPHROPATHY; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN BLOOD LEVEL; PROTEIN DEGRADATION; PROTEIN METABOLISM; PROTEIN URINE LEVEL; ADOLESCENT; AGED; BLOOD; EXTRACELLULAR MATRIX; GLOMERULONEPHRITIS, IGA; INFLAMMATION; METABOLISM; MIDDLE AGED; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; BIOMARKERS; COLLAGEN TYPE III; DISEASE PROGRESSION; ENZYME-LINKED IMMUNOSORBENT ASSAY; EXTRACELLULAR MATRIX; FEMALE; GLOMERULONEPHRITIS, IGA; HUMANS; INFLAMMATION; MALE; MIDDLE AGED; PROGNOSIS; YOUNG ADULT;

EID: 84960129541     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfv301     Document Type: Article

References (33)

1. Boor P, Ostendorf T, Floege J. Renal fibrosis: novel insights into mechanisms and therapeutic targets. Nat Rev Nephrol 2010; 6: 643-656
2. Barbour SJ, Reich HN. Risk stratification of patients with IgA nephropathy. Am J Kidney Dis 2012; 59: 865-873
3. Miyata T, Ando T, Hiragi H, et al. Drug discovery in renal disease-towards a more efficient framework. Nat Rev Nephrol 2014; 10: 290-296
4. Soylemezoglu O, Wild G, Dalley AJ, et al. Urinary and serum type III collagen: markers of renal fibrosis. Nephrol Dial Transplant 1997; 12: 1883-1889
5. Zeisberg M, Bonner G, Maeshima Y, et al. Renal fibrosis: collagen composition and assembly regulates epithelial-mesenchymal transdifferentiation. Am J Pathol 2001; 159: 1313-1321
6. Good DM, Zurbig P, Argiles A, et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010; 9: 2424-2437
7. Liu Y. Cellular and molecular mechanisms of renal fibrosis. Nat Rev Nephrol 2011; 7: 684-696
8. Genovese F, Manresa AA, Leeming DJ, et al. The extracellular matrix in the kidney: a source of novel non-invasive biomarkers of kidney fibrosis? Fibrogenesis Tissue Repair 2014; 7: 4
9. Nielsen MJ, Nedergaard AF, Sun S, et al. The neo-epitope specific PRO-C3 ELISA measures true formation of type III collagen associated with liver and muscle parameters. Am J Transl Res 2013; 5: 303-315
10. Barascuk N, Veidal SS, Larsen L, et al. A novel assay for extracellular matrix remodeling associated with liver fibrosis: an enzyme-linked immunosorbent assay (ELISA) for a MMP-9 proteolytically revealed neo-epitope of type III collagen. Clin Biochem 2010; 43: 899-904
11. Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med 2013; 368: 2402-2414
12. Floege J, Feehally J. Treatment of IgA nephropathy and Henoch-Schonlein nephritis. Nat Rev Nephrol 2013; 9: 320-327
13. Ghoul BE, Squalli T, Servais A, et al. Urinary procollagen III aminoterminalpropeptide (PIIINP): a fibrotest for the nephrologist. Clin J Am Soc Nephrol 2010; 5: 205-210
14. Teppo AM, Tornroth T, Honkanen E, et al. Urinary amino-terminal propeptide of type III procollagen (PIIINP) as a marker of interstitial fibrosis in renal transplant recipients. Transplantation 2003; 75: 2113-2119
15. Ix JH, Biggs ML, Mukamal K, et al. Urine collagen fragments and CKD progression-The Cardiovascular Health Study. J Am Soc Nephrol 2015; 26: doi: 10.1681/ASN.2014070696
16. Prockop DJ, Sieron AL, Li SW. Procollagen N-proteinase and procollagen C-proteinase. Two unusual metalloproteinases that are essential for procollagen processing probably have important roles in development and cell signalling. Matrix Biol 1998; 16: 399-408
17. Guder WG, Hofmann W. Clinical role of urinary low molecularweight proteins: their diagnostic and prognostic implications. Scand J Clin Lab Invest Suppl 2008; 241: 95-98
18. Spanaus KS, Kollerits B, Ritz E, et al. Serum creatinine, cystatin C, and betatrace protein in diagnostic staging and predicting progression of primary nondiabetic chronic kidney disease. Clin Chem 2010; 56: 740-749
19. Woitas RP, Stoffel-Wagner B, PoegeU, et al. Low-molecular weight proteins as markers for glomerular filtration rate. Clin Chem 2001; 47: 2179-2180
20. Karsdal MA, Bay-Jensen AC, Leeming DJ, et al. Quantification of 'end products' of tissue destruction in inflammation may reflect convergence of cytokine and signaling pathways -implications for modern clinical chemistry. Biomarkers 2013; 18: 375-378
21. Karsdal MA, Krarup H, Sand JM, et al. Reviewarticle: the efficacy of biomarkers in chronic fibroproliferative diseases -early diagnosis and prognosis, with liver fibrosis as an exemplar. Aliment Pharmacol Ther 2014; 40: 233-249
22. Eitner F, Ackermann D, Hilgers RD, et al. Supportive versus immunosuppressive therapy of progressive IgA nephropathy (STOP) IgAN trial: rationale and study protocol. J Nephrol 2008; 21: 284-289
23. Gu YM, Thijs L, Liu YP, et al. The urinary proteome as correlate and predictor of renal function in a population study. Nephrol Dial Transplant 2014; 29: 2260-2268
24. Ling XB, Sigdel TK, Lau K, et al. Integrative urinary peptidomics in renal transplantation identifies biomarkers for acute rejection. J AmSoc Nephrol 2010; 21: 646-653
25. Kuznetsova T, Mischak H, Mullen W, et al. Urinary proteome analysis in hypertensive patients with left ventricular diastolic dysfunction. Eur Heart J 2012; 33: 2342-2350
26. Janssen U, Bahlmann F, Kohl J, et al. Activation of the acute phase response and complement C3 in patients with IgA nephropathy. Am J Kidney Dis 2000; 35: 21-28
27. Nielsen MJ, Veidal SS, Karsdal MA. Plasma Pro-C3 (N-terminal type III collagen propeptide) predicts fibrosis progression in patients with chronic hepatitis C. Liver Int 2015; doi: 10.1111/liv.12700
28. Leeming DJ, Sand JM, Nielsen MJ, et al. Serological investigation of the collagen degradation profile of patients with chronic obstructive pulmonary disease or idiopathic pulmonary fibrosis. Biomark Insights 2012; 7: 119-126
29. Leeming DJ, Anadol E, Schierwagen R, et al. Combined antiretroviral therapy attenuates hepatic extracellular matrix remodeling in HIV patients assessed by novel protein fingerprint markers. AIDS 2014; 28: 2081-2090
30. Papasotiriou M, Genovese F, Klinkhammer BMet al. Serum and urine markers of collagen degradation reflect renal fibrosis in experimental kidney diseases. Nephrol Dial Transplant 2015; 30: 1112-1121
31. Vassiliadis E, Larsen DV, Clausen RE, et al. Measurement of CO3-610, a potential liver biomarker derived from matrix metalloproteinase-9 degradation of collagen type iii, in a rat model of reversible carbon-tetrachlorideinduced fibrosis. Biomarker Insights 2011; 6: 49-58
32. Hodgkins KS, Schnaper HW. Tubulointerstitial injury and the progression of chronic kidney disease. Pediatr Nephrol 2012; 27: 901-909
33. Metcalfe W. How does early chronic kidney disease progress? A background paper prepared for the UK consensus conference on early chronic kidney disease. Nephrol Dial Transplant 2007; 22(Suppl 9): ix26-ix30